NEW YORK – The National Comprehensive Cancer Network has updated its guidelines for genetic testing to assess the risk of breast, ovarian and pancreatic cancer.
"These NCCN guidelines still have a strong focus on BRCA1 and [BRCA]2 mutations, but also now include other high- and moderate-penetrance genes associated with breast, ovarian, and pancreatic cancer," Mary Daly from Fox Chase Cancer Center and the chair of the guidelines panel said in a statement.